Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Resectable Head and Neck Cancer and Non-small Cell Lung Cancer
2021-004189-37Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, laryngeal squamous cell carcinoma (LSCC) and 3 more (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Biological effect on autophagy and immune markers. Started Aug 2021; status: active.
02
Drugs
hydroxychloroquine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomalaryngeal squamous cell carcinoma (LSCC)non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2021-004189-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004189-37.